The stock of INTELLIPHARMACEUTICS INTL INC COMMON SHA (OTCMKTS:IPCIF) registered a decrease of 0.51% in short interest. IPCIF’s total short interest was 19,700 shares in September as published by FINRA. Its down 0.51% from 19,800 shares, reported previously. With 79,700 shares average volume, it will take short sellers 0 days to cover their IPCIF’s short positions.

The stock decreased 1.77% or $0.0034 during the last trading session, reaching $0.19. About 76,382 shares traded. Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) has 0.00% since September 13, 2018 and is . It has by 0.00% the S&P500.

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and makes novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. The company has market cap of $4.22 million. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. It currently has negative earnings. The firm offers Oxycodone ER, an abuse deterrent oxycodone hydrochloride extended release tablet; Regabatin and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; Protonix, a pantoprazole sodium delayed-release capsule to treat gastroesophageal reflux disease; and Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.